Overview
Properties
Constituents: 10% Trehalose, 1% Human serum albumin, PBS
Concentration information loading...Applications
Our Abpromise guarantee covers the use of ab83827 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Notes |
|---|---|
| SDS-PAGE |
Molecular Mass: ab83827 migrates as a broad band between 75 and 90 kDa in SDS-PAGE due to post-translation modifications, in particular glycosylation. This compares
with the unmodified IL7R alpha-Fc Chimera that has a predicted molecular mass of 50.0kDa.
pI: ab83827 separates into a number of isoforms with a pI between 5.9 and 7.4 in 2D PAGE due to post-translational modifications, in particular glycosylation. This compares with the unmodified IL7R alpha-Fc Chimera that has a predicted pI of 6.34.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Protein info
-
Alternative names
- CD 127CD127CD127 antigen
- CDW127IL 7RIL 7R alphaIL-7 receptor subunit alphaIL-7R subunit alphaIL-7R-alphaIL-7RAIL7RIL7RAIL7RA_HUMANIL7RalphaILRAInterleukin 7 receptorInterleukin 7 receptor alpha chainInterleukin 7 receptor isoform H5 6Interleukin-7 receptor subunit alpha
see all
Genetic variations in IL7R are a cause of susceptibility to multiple sclerosis type 3 (MS3) [MIM:612595]. A multifactorial, inflammatory, demyelinating disease of the central nervous system. Sclerotic lesions are characterized by perivascular infiltration of monocytes and lymphocytes and appear as indurated areas in pathologic specimens (sclerosis in plaques). The pathological mechanism is regarded as an autoimmune attack of the myelin sheat, mediated by both cellular and humoral immunity. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia and bladder dysfunction. Genetic and environmental factors influence susceptibility to the disease. Note=A polymorphism at position 244 strongly influences susceptibility to multiple sclerosis. Overtransmission of the major 'C' allele coding for Thr-244 is detected in offspring affected with multiple sclerosis. In vitro analysis of transcripts from minigenes containing either 'C' allele (Thr-244) or 'T' allele (Ile-244) shows that the 'C' allele results in an approximately two-fold increase in the skipping of exon 6, leading to increased production of a soluble form of IL7R. Thus, the multiple sclerosis associated 'C' risk allele of IL7R would probably decrease membrane-bound expression of IL7R. As this risk allele is common in the general population, some additional triggers are probably required for the development and progression of MS.
Contains 1 fibronectin type-III domain.
The box 1 motif is required for JAK interaction and/or activation.
modificationsN-glycosylated IL-7Ralpha binds IL7 300-fold more tightly than the unglycosylated form.
Target information above from: UniProt accession
P16871
The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010)
.
IL7R alpha protein (Fc Chimera) images
-
Functional Studies - IL7 protein (Fc Chimera) (ab83827)Densitometry of protein isoforms visualised by 2-DE.
The densitometry scan demonstrates the purified human cell expressed protein exists in multiple isoforms, which differ according to their level of post-translational modification.
The triangle indicates the theoretical MW and pI of the protein. -
SDS-PAGE - IL7 protein (Fc Chimera) (ab83827)1D SDS-PAGE of ab83827 before and after treatment with glycosidases to remove oligosaccharides.
Lane 1: ab83827
Lane 2: ab83827 treated with PNGase F to remove potential N-linked glycans
10 µg protein loaded per lane; Deep Purple™ stained.
Drop in MW after treatment with PNGase F indicates presence of N-linked glycans.
References for IL7R alpha protein (Fc Chimera) (ab83827)
ab83827 has not yet been referenced specifically in any publications.
